An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma

Graham, 2018, Prognostication in kidney cancer: recent advances and future directions, J Clin Oncol, 36, 3567, 10.1200/JCO.2018.79.0147 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Motzer, 2019, NCCN clinical practice guidelines in oncology: kidney cancer 3.2019, J Natl Compr Canc Netw Powles, 2018, Updated European Association of Urology guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer, Eur Urol, 73, 311, 10.1016/j.eururo.2017.11.016 Escudier, 2019, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 10.1093/annonc/mdz056 Beuselinck, 2015, Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting, Clin Cancer Res, 21, 1329, 10.1158/1078-0432.CCR-14-1128 Beuselinck, 2018, Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk, Ann Oncol, 29, 10.1093/annonc/mdy283.078 Rini, 2018, Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC), Ann Oncol, 29, 10.1093/annonc/mdy424.037 Miao, 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science, 359, 801, 10.1126/science.aan5951 Carlo, 2017, Genomic alterations and outcomes with VEGF-targeted therapy in patients with clear cell renal cell carcinoma, Kidney Cancer, 1, 49, 10.3233/KCA-160003 Derosa, 2018, Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer, Ann Oncol, 29, 1437, 10.1093/annonc/mdy103 Dizman, 2018, Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC), Ann Oncol, 29, 10.1093/annonc/mdy283.103 Sun, 2018, Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance, Ann Oncol, 29, 10.1093/annonc/mdy283.095 Maia, 2018, Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC), J Clin Oncol, 36, 662, 10.1200/JCO.2018.36.6_suppl.662 Rodriguez-Vida, 2016, Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma, ESMO Open, 1, 10.1136/esmoopen-2015-000013 Heng, 2013, External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study, Lancet Oncol, 14, 141, 10.1016/S1470-2045(12)70559-4